Airway Institute in Sendai Co., Ltd., Miyagi, Japan. tamura@airway−sendai.com
Allergol Int. 2012 Jun;61(2):219-29. doi: 10.2332/allergolint.11-RA-0358. Epub 2012 Jan 25.
Tulobuterol patch (HokunalinTM Tape), which contains a β(2)-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides with the morning dip in respiratory function. The use of the patch also prevents excessive increase in blood drug concentrations, thereby reducing the incidence of systemic adverse reactions. Since 1998, when it was first approved in Japan and worldwide, the tulobuterol patch has been used widely in the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD), and evidence collected since it was approved has confirmed its clinical efficacy and safety. Because the patch is easy to use and requires only once-daily application, treatment adherence of patients using the patch is good. In this article, we discuss the rationale behind the development of the tulobuterol patch, evaluate data on its clinical efficacy and safety in the treatment of asthma and COPD, and examine the treatment adherence in individuals using the patch.
特布他林贴片（喘可治贴）是第一个可用于透皮贴剂的β（2）-肾上腺素能受体激动剂，这种药物传递系统确保了血液中药物浓度达到峰值的时间与呼吸功能在清晨下降的时间相吻合。使用贴片还可以防止血液中药物浓度的过度增加，从而减少全身不良反应的发生。自 1998 年在日本和全球首次批准以来，特布他林贴片已广泛用于治疗支气管哮喘和慢性阻塞性肺疾病（COPD），自批准以来收集的证据证实了其临床疗效和安全性。由于贴片使用方便，每天只需使用一次，因此使用贴片的患者治疗依从性良好。本文讨论了特布他林贴片开发的基本原理，评估了其在治疗哮喘和 COPD 中的临床疗效和安全性数据，并考察了使用贴片的个体的治疗依从性。
